Joe Hirman

发表

Davunetide for progressive supranuclear palsy: Results of the AL-108-231, phase 2/3, 52 week, multi-center, randomized, double-blind, placebo-controlled clinical trial

Andrew J. Lees, Murray Grossman, Anthony E. Lang, 2013 .

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Clifford R Jack, Murray Grossman, Albert Ludolph, 2014, The Lancet Neurology.